CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection

Oncoimmunology. 2012 Jul 1;1(4):544-546. doi: 10.4161/onci.19442.

Abstract

We report that cryoablation of primary tumors synergizes with anti-CTLA-4 treatment to mediate rejection of secondary tumors in the TRAMP mouse model of prostate cancer. T cells, in particular CD8(+) T cells specific for the TRAMP antigen SPAS-1, were enriched in both secondary tumors and spleens of combination-treated mice.